RBC Capital: 'What's Regeneron Pharma's (REGN) Best Next Move'

RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $662.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst commented: "What's REGN's Best Next Move? REGN is in somewhat of a challenging place following itepekimab's failure, with Eylea franchise erosion and dupi LOE remaining persistent overhangs on the narrative and pipeline catalysts and dupi COPD uptake not seeming major enough to help shares break out near-term (noting yesterday's muted stock reaction to obesity data/deal). We do believe shares are fundamentally undervalued, so we explore in more depth 5 approaches the company could take to help catalyze sentiment improvement and stock upside, including accelerating share buybacks, pursuing more transformative BD, clarifying dupi life cycle plans, divesting or expanding the ophtho franchise, and/or broadening decision-makers within mgmt."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $490.81 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy